Caas Capital Management LP Dexcom Inc Transaction History

Caas Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$104.0 - $122.92 $166,400 - $196,672	1,600 New	1,600 $185,000
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $342,277 - $422,208	-4,483 Reduced 6.44%	65,097 $5.24 Million
Q2 2022 Aug 15, 2022	BUY	$67.99 - $132.89 $4.35 Million - $8.51 Million	64,009 Added 1148.97%	69,580 $5.19 Million
Q2 2021 Aug 16, 2021	SELL	$80.99 - $107.93 $859,951 - $1.15 Million	-10,618 Reduced 65.59%	5,571 $2.38 Million
Q1 2021 May 17, 2021	BUY	$84.79 - $104.74 $609,555 - $752,975	7,189 Added 79.88%	16,189 $5.82 Million
Q4 2020 Feb 12, 2021	BUY	$78.0 - $104.5 $702,000 - $940,500	9,000 New	9,000 $3.33 Million

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.